The global population is aging due to declining birth rates and increased life expectancy, creating significant challenges for public health systems, ...

Initiation of the Phase 2 EMPOWER trial of ARD-201 for the treatment of obesity and obesity-related conditions as a fixed-dose combination of ARD-101 with a dipeptidyl peptidase-4 (DPP-4) inhibitor is ...

Task: Navigating an autoimmune condition Occupation: CEO and co-founder of WellTheory, a platform for autoimmune care ...

Whether you’re on a weight loss journey of your own or not, you probably haven’t been able to avoid hearing about the sudden ...

GLP-1 medications are reshaping the weight management landscape — and beginning to take a bite out of bariatric surgery volumes in hospitals. Between 2022 and 2023, bariatric surgery rates fell 25.6% ...

As the indications and demand for glucagon-like peptide-1 (GLP-1) agonist drugs continue to expand, the real-world GLP-1 research and data-driven insights from Prime Therapeutics LLC (Prime) help ...

Ask a Doctor is new series of physician-authored columns offering insights and advice on common health topics. It is not a ...

According to the journal Second Nature, Mounjaro supports weight loss of around four per cent of body weight after one month, ...

A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases ...

WalletHub compiled a list of top 10 'fattest cities in America' based on obesity rates, proximity to fresh food, and access ...

Comparing a soda ban to COVID authoritarianism might make for a catchy tweet, but it’s intellectually dishonest — and ...